130 related articles for article (PubMed ID: 35487832)
1. Passive and receptor mediated brain delivery of an anti-GFAP nanobody.
Meier SR; Sehlin D; Syvänen S
Nucl Med Biol; 2022; 114-115():121-127. PubMed ID: 35487832
[TBL] [Abstract][Full Text] [Related]
2. Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies.
Faresjö R; Lindberg H; Ståhl S; Löfblom J; Syvänen S; Sehlin D
Pharm Res; 2022 Jul; 39(7):1509-1521. PubMed ID: 35538266
[TBL] [Abstract][Full Text] [Related]
3. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.
Faresjö R; Sehlin D; Syvänen S
Fluids Barriers CNS; 2023 May; 20(1):34. PubMed ID: 37170266
[TBL] [Abstract][Full Text] [Related]
4. Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging.
Gustavsson T; Herth MM; Sehlin D; Syvänen S
Ups J Med Sci; 2024; 129():. PubMed ID: 38863725
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease.
Rofo F; Metzendorf NG; Saubi C; Suominen L; Godec A; Sehlin D; Syvänen S; Hultqvist G
Alzheimers Res Ther; 2022 Dec; 14(1):180. PubMed ID: 36471433
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
[TBL] [Abstract][Full Text] [Related]
7. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Syvänen S; O'Callaghan P; Sehlin D
Transl Neurodegener; 2020 Sep; 9(1):37. PubMed ID: 32951598
[TBL] [Abstract][Full Text] [Related]
8. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease.
Meier SR; Sehlin D; Hultqvist G; Syvänen S
Mol Imaging Biol; 2021 Oct; 23(5):665-675. PubMed ID: 33620643
[TBL] [Abstract][Full Text] [Related]
9. A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice.
Rofo F; Meier SR; Metzendorf NG; Morrison JI; Petrovic A; Syvänen S; Sehlin D; Hultqvist G
Neurotherapeutics; 2022 Sep; 19(5):1588-1602. PubMed ID: 35939261
[TBL] [Abstract][Full Text] [Related]
10. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.
Syvänen S; Hultqvist G; Gustavsson T; Gumucio A; Laudon H; Söderberg L; Ingelsson M; Lannfelt L; Sehlin D
Alzheimers Res Ther; 2018 May; 10(1):49. PubMed ID: 29793530
[TBL] [Abstract][Full Text] [Related]
11. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain.
Fang XT; Hultqvist G; Meier SR; Antoni G; Sehlin D; Syvänen S
Neuroimage; 2019 Jan; 184():881-888. PubMed ID: 30300753
[TBL] [Abstract][Full Text] [Related]
12. A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging.
Syvänen S; Fang XT; Hultqvist G; Meier SR; Lannfelt L; Sehlin D
Neuroimage; 2017 Mar; 148():55-63. PubMed ID: 28069541
[TBL] [Abstract][Full Text] [Related]
13.
Meier SR; Sehlin D; Roshanbin S; Falk VL; Saito T; Saido TC; Neumann U; Rokka J; Eriksson J; Syvänen S
J Nucl Med; 2022 Feb; 63(2):302-309. PubMed ID: 34088777
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Metzendorf NG; Wik E; Roshanbin S; Julku U; Chourlia A; Nilsson P; Andersson KG; Laudon H; Hultqvist G; Syvänen S; Sehlin D
Alzheimers Res Ther; 2023 May; 15(1):90. PubMed ID: 37131196
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 18F labeled glial fibrillary acidic protein binding nanobody and its brain shuttle peptide fusion proteins using a neuroinflammation rat model.
Morito T; Harada R; Iwata R; Ishikawa Y; Okamura N; Kudo Y; Furumoto S; Yanai K; Tashiro M
PLoS One; 2023; 18(6):e0287047. PubMed ID: 37315033
[TBL] [Abstract][Full Text] [Related]
16. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
[TBL] [Abstract][Full Text] [Related]
17. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.
Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D
MAbs; 2024; 16(1):2339337. PubMed ID: 38634473
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of alpha-synuclein with antibody-based PET.
Roshanbin S; Xiong M; Hultqvist G; Söderberg L; Zachrisson O; Meier S; Ekmark-Lewén S; Bergström J; Ingelsson M; Sehlin D; Syvänen S
Neuropharmacology; 2022 May; 208():108985. PubMed ID: 35149134
[TBL] [Abstract][Full Text] [Related]
19. Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer's related amyloid-beta pathology.
Su S; Esparza TJ; Brody DL
PLoS One; 2022; 17(10):e0276107. PubMed ID: 36256604
[TBL] [Abstract][Full Text] [Related]
20. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size.
Faresjö R; Bonvicini G; Fang XT; Aguilar X; Sehlin D; Syvänen S
Fluids Barriers CNS; 2021 Jun; 18(1):26. PubMed ID: 34078410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
